Back to News
Market Impact: 0.15
Editas Medicine Names Dan Ory Chief Medical Officer
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Editas Medicine appointed biotechnology executive Dan Ory as chief medical officer, effective September 8. The leadership change is a routine operational development with limited expected near-term market impact absent additional clinical, strategic, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
EDIT0.30
More News
- Editas Medicine at Wells Fargo conference: a focused bet on CRISPR
- Apple's $2000+ iPhone, Oil Gain Stokes Inflation Fear | Bloomberg Businessweek Daily 9/8/2026
- Stock Movers: Chime, Stryker, Compass Pathways (Podcast)
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026